A concise panel of biomarkers identifies neurocognitive functioning changes in HIV-infected individuals

Journal of Neuroimmune Pharmacology

Volumn 8, Issue 5, 2013, Pages 1123-1135

  Marcotte, Thomas D ^a   Deutsch, Reena ^a   Michael, Benedict Daniel ^b   Franklin, Donald ^a   Cookson, Debra Rosario ^a   Bharti, Ajay R ^c   Grant, Igor ^a   Letendre, Scott L ^c,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Biomarkers; Cerebrospinal Fluid; HIV; Neurocognitive Disorders

Indexed keywords

BIOLOGICAL MARKER; CD14 ANTIGEN; FRACTALKINE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; SOLUBLE CD14 ANTIGEN; STROMAL CELL DERIVED FACTOR 1ALPHA; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 2; UNCLASSIFIED DRUG;

BLOOD SAMPLING; CD4 LYMPHOCYTE COUNT; CEREBROSPINAL FLUID; COGNITIVE DEFECT; COMPREHENSION; DISEASE COURSE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IMMUNOASSAY; LUMBAR PUNCTURE; PHLEBOTOMY; PRIORITY JOURNAL; REVIEW;

ADULT; AIDS DEMENTIA COMPLEX; BIOLOGICAL MARKERS; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; SENSITIVITY AND SPECIFICITY;

EID: 84891353885     PISSN: 15571890     EISSN: 15571904     Source Type: Journal    
DOI: 10.1007/s11481-013-9504-2     Document Type: Review

References (49)

1. Achim CL, Heyes MP, Wiley CA (1993) Quantitation of human immunodeficiency virus, immune activation factors, and quinolinic acid in AIDS brains. J clin investig 91(6):2769-2775. doi: 10.1172/JCI116518
2. Antinori A, Arendt G, Becker JT, Brew BJ, Byrd DA, Cherner M, Clifford DB, Cinque P, Epstein LG, Goodkin K, Gisslen M, Grant I, Heaton RK, Joseph J, Marder K, Marra CM, McArthur JC, Nunn M, Price RW, Pulliam L, Robertson KR, Sacktor N, Valcour V, Wojna VE (2007) Updated research nosology for HIV-associated neurocognitive disorders. Neurology 69(18):1789-1799
3. Breiman L, Friedman JH, Olshen RA, Stone CJ (1984) Classification and regression trees. Wadsworth International Group, Belmont
4. Burdo TH, Weiffenbach A, Woods SP, Letendre S, Ellis RJ, Williams KC (2013) Elevated sCD163 is a marker of neurocognitive impairment in HIV infection. AIDS
5. Carey CL, Woods SP, Gonzalez R, Conover E, Marcotte TD, Grant I, Heaton RK (2004) Predictive validity of global deficit scores in detecting neuropsychological impairment in HIV infection. J clin exp neuropsychol 26(3):307-319. doi: 10.1080/13803390490510031
6. Conant K, Garzino-Demo A, Nath A, McArthur JC, Halliday W, Power C, Gallo RC, Major EO (1998) Induction of monocyte chemoattractant protein-1 in HIV-1 Tat-stimulated astrocytes and elevation in AIDS dementia. Proc Natl Acad Sci U S A 95(6):3117-3121
7. Crowe SM, Westhorpe CL, Mukhamedova N, Jaworowski A, Sviridov D, Bukrinsky M (2010) The macrophage: the intersection between HIV infection and atherosclerosis. J leukoc biol 87(4):589-598. doi: 10.1189/jlb.0809580
8. Cysique LA, Franklin D Jr, Abramson I, Ellis RJ, Letendre S, Collier A, Clifford D, Gelman B, McArthur J, Morgello S, Simpson D, McCutchan JA, Grant I, Heaton RK (2011) Normative data and validation of a regression based summary score for assessing meaningful neuropsychological change. J clin exp neuropsychol 33(5):505-522. doi: 10.1080/13803395.2010.535504
9. Cysique LA, Vaida F, Letendre S, Gibson S, Cherner M, Woods SP, McCutchan JA, Heaton RK, Ellis RJ (2009) Dynamics of cognitive change in impaired HIV-positive patients initiating antiretroviral therapy. Neurology 73(5):342-348. doi: 10.1212/WNL.0b013e3181ab2b3b
10. Ellis RJ, Badiee J, Vaida F, Letendre S, Heaton RK, Clifford D, Collier AC, Gelman B, McArthur J, Morgello S, McCutchan JA, Grant I, CHARTER Group (2011) CD4 nadir is a predictor of HIV neurocognitive impairment in the era of combination antiretroviral therapy. AIDS 25(14):1747-1751
11. Fields J, Dumaop W, Rockenstein E, Mante M, Spencer B, Grant I, Ellis R, Letendre S, Patrick C, Adame A, Masliah E (2013) Age-dependent molecular alterations in the autophagy pathway in HIVE patients and in a gp120 tg mouse model: reversal with beclin-1 gene transfer. J Neurovirol 19(1):89-101
12. Gartner S, Liu Y (2002) Insights into the role of immune activation in HIV neuropathogenesis. J Neurovirol 8(2):69-75
13. Gonzalez E, Rovin BH, Sen L, Cooke G, Dhanda R, Mummidi S, Kulkarni H, Bamshad MJ, Telles V, Anderson SA, Walter EA, Stephan KT, Deucher M, Mangano A, Bologna R, Ahuja SS, Dolan MJ, Ahuja SK (2002) HIV-1 infection and AIDS dementia are influenced by a mutant MCP-1 allele linked to increased monocyte infiltration of tissues and MCP-1 levels. Proc Natl Acad Sci U S A 99(21):13795-13800. doi: 10.1073/pnas.202357499
14. Gruol DL, Nelson TE (1997) Physiological and pathological roles of interleukin-6 in the central nervous system. Mol neurobiol 15(3):307-339. doi: 10.1007/BF02740665
15. Heaton RK, Clifford DB, Franklin DR Jr, Woods SP, Ake C, Vaida F, Ellis RJ, Letendre SL, Marcotte TD, Atkinson JH, Rivera-Mindt M, Vigil OR, Taylor MJ, Collier AC, Marra CM, Gelman BB, McArthur JC, Morgello S, Simpson DM, McCutchan JA, Abramson I, Gamst A, Fennema-Notestine C, Jernigan TL, Wong J, Grant I (2010) HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. Neurology 75(23):2087-2096. doi: 10.1212/WNL.0b013e318200d727
16. Heaton RK, Franklin DR, Ellis RJ, McCutchan JA, Letendre SL, Leblanc S, Corkran SH, Duarte NA, Clifford DB, Woods SP, Collier AC, Marra CM, Morgello S, Mindt MR, Taylor MJ, Marcotte TD, Atkinson JH, Wolfson T, Gelman BB, McArthur JC, Simpson DM, Abramson I, Gamst A, Fennema-Notestine C, Jernigan TL, Wong J, Grant I (2011) HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. J Neurovirol 17(1):3-16. doi: 10.1007/s13365-010-0006-1
17. Kamat A, Lyons JL, Misra V, Uno H, Morgello S, Singer EJ, Gabuzda D (2012) Monocyte activation markers in cerebrospinal fluid associated with impaired neurocognitive testing in advanced HIV infection. J Acquir Immune Defic Syndr 60(3):234-243. doi: 10.1097/QAI.0b013e318256f3bc
18. Kelder W, McArthur JC, Nance-Sproson T, McClernon D, Griffin DE (1998) Beta-chemokines MCP-1 and RANTES are selectively increased in cerebrospinal fluid of patients with human immunodeficiency virus-associated dementia. Ann Neurol 44(5):831-835
19. Kennedy PG (1988) Neurological complications of human immunodeficiency virus infection. Postgrad Med J 64(749):180-187
20. Letendre S (2011) Central nervous system complications in HIV disease: HIV-associated neurocognitive disorder. Top Antivir Med 19(4):137-142
21. Letendre SL, Zheng JC, Kaul M, Yiannoutsos CT, Ellis RJ, Taylor MJ, Marquie-Beck J, Navia B (2011) Chemokines in cerebrospinal fluid correlate with cerebral metabolite patterns in HIV-infected individuals. J Neurovirol 17(1):63-69. doi: 10.1007/s13365-010-0013-2
22. Lien E, Aukrust P, Sundan A, Müller F, Frøland SS, Espevik T (1998) Elevated levels of serum-soluble CD14 in human immunodeficiency virus type 1 (HIV-1) infection: correlation to disease progression and clinical events. Blood 92(6):2084-2092
23. Lyons JL, Uno H, Ancuta P, Kamat A, Moore DJ, Singer EJ, Morgello S, Gabuzda D (2011) Plasma sCD14 is a biomarker associated with impaired neurocognitive test performance in attention and learning domains in HIV infection. J Acquir Immune Defic Syndr 57(5):371-379. doi: 10.1097/QAI. 0b013e3182237e54
24. Marcotte TD, Wolfson T, Rosenthal TJ, Heaton RK, Gonzalez R, Ellis RJ, Grant I, HIV Neurobehavioral Research Center Group (2004) A multimodal assessment of driving performance in HIV infection. Neurology 63(8):1417-1422
25. Mastroianni CM, Paoletti F, Massetti AP, Falciano M, Vullo V (1990) Elevated levels of tumor necrosis factor (TNF) in the cerebrospinal fluid from patients with HIV-associated neurological disorders. Acta neurol 12(1):66-67
26. McArthur J, Smith B (2013) Neurologic complications and considerations in HIV-infected persons. Curr Infect Dis Rep 15(1):61-66
27. McPhail ME, Robertson K (2011) Neurocognitive impact of antiretroviral treatment: thinking long-term. Curr HIV/AIDS Rep 8(4):249-256
28. Monteiro de Almeida S, Letendre S, Zimmerman J, Lazzaretto D, McCutchan A, Ellis R (2005) Dynamics of monocyte chemoattractant protein type one (MCP-1) and HIV viral load in human cerebrospinal fluid and plasma. J Neuroimmunol 169(1-2):144-152. doi: 10.1016/j.jneuroim.2005.07.012
29. Nixon DE, Landay AL (2010) Biomarkers of immune dysfunction in HIV. Curr opin HIV AIDS 5(6):498-503. doi: 10.1097/COH.0b013e32833ed6f4
30. Nockher WA, Bergmann L, Scherberich JE (1994) Increased soluble CD14 serum levels and altered CD14 expression of peripheral blood monocytes in HIV-infected patients. Clin Exp Immunol 98(3):369-374
31. Perrella O, Carrieri PB, Guarnaccia D, Soscia M (1992) Cerebrospinal fluid cytokines in AIDS dementia complex. J neurol 239(7):387-388
32. Poquette AJ, Moore D, Gouaux B, Morgan EE, Grant I, Woods SP, HNRP Group (2013) Prospective memory and antiretroviral medication non-adherence in HIV: an analysis of ongoing task delay length using the memory for intentions screening test. J Int Neuropsychol Soc 19(2):155-161
33. Pulliam L, Gascon R, Stubblebine M, McGuire D, McGrath MS (1997) Unique monocyte subset in patients with AIDS dementia. Lancet 349(9053):692-695
34. Rackstraw S (2011) HIV-related neurocognitive impairment-a review. Psychol Health Med 16(5):548-563. doi: 10.1080/13548506.2011.579992
35. Rodriguez-Penney AT, Iudicello J, Riggs PK, Doyle K, Ellis RJ, Letendre SL, Grant I, Woods SP, HIV Neurobehavioral Research Program HNRP Group (2013) Co-morbidities in persons infected with HIV: increased burden with older age and negative effects on health-related quality of life. AIDS Patient Care STDS 27(1):5-16
36. Ryan LA, Zheng J, Brester M, Bohac D, Hahn F, Anderson J, Ratanasuwan W, Gendelman HE, Swindells S (2001) Plasma levels of soluble CD14 and tumor necrosis factor-alpha type II receptor correlate with cognitive dysfunction during human immunodeficiency virus type 1 infection. J Infect Dis 184(6):699-706. doi: 10.1086/323036
37. Sanders VJ, Pittman CA, White MG, Wang G, Wiley CA, Achim CL (1998) Chemokines and receptors in HIV encephalitis. AIDS 12(9):1021-1026
38. Simioni S, Cavassini M, Annoni JM, Rimbault Abraham A, Bourquin I, Schiffer V, Calmy A, Chave JP, Giacobini E, Hirschel B, Du Pasquier RA (2010) Cognitive dysfunction in HIV patients despite long-standing suppression of viremia. AIDS 24(9):1243-1250. doi: 10.1097/QAD.0b013e3283354a7b
39. Singh KK, Ellis RJ, Marquie-Beck J, Letendre S, Heaton RK, Grant I, Spector SA (2004) CCR2 polymorphisms affect neuropsychological impairment in HIV-1-infected adults. J Neuroimmunol 157(1-2):185-192. doi: 10.1016/j.jneuroim.2004.08.027
40. Sun B, Abadjian L, Rempel H, Calosing C, Rothlind J, Pulliam L (2010) Peripheral biomarkers do not correlate with cognitive impairment in highly active antiretroviral therapy-treated subjects with human immunodeficiency virus type 1 infection. J Neurovirol 16(2):115-124. doi: 10.3109/13550280903559789
41. Temkin NR, Heaton RK, Grant I, Dikmen SS (1999) Detecting significant change in neuropsychological test performance: a comparison of four models. J Int Neuropsychol Soc 5(4):357-369
42. Thiébaut R, Charpentier C, Damond F, Taieb A, Antoine R, Capeau J, Chêne G, Collin G, Matheron S, Descamps D, Brun-Vézinet F, French ANRS HIV-2 CO5 Cohort (2012) Association of soluble CD14 and inflammatory biomarkers with HIV-2 disease progression. Clin Infect Dis 55(10):1417-1425
43. Thieblemont N, Weiss L, Sadeghi HM, Estcourt C, Haeffner-Cavaillon N (1995) CD14lowCD16high: a cytokine-producing monocyte subset which expands during human immunodeficiency virus infection. Eur J Immunol 25(12):3418-3424
44. Vullo V, Mastroianni CM, Lichtner M, Mengoni F, Delia S (1995) Increased cerebrospinal fluid levels of soluble receptors for tumour necrosis factor in HIV-infected patients with neurological diseases. AIDS 9(9):1099-1100
45. Weiss JM, Nath A, Major EO, Berman JW (1999) HIV-1 Tat induces monocyte chemoattractant protein-1-mediated monocyte transmigration across a model of the human blood-brain barrier and up-regulates CCR5 expression on human monocytes. J Immunol 163(5):2953-2959
46. Wesselingh SL, Glass J, McArthur JC, Griffin JW, Griffin DE (1994) Cytokine dysregulation in HIV-associated neurological disease. Adv neuroimmunol 4(3):199-206
47. Yuan L, Qiao L, Wei F, Yin J, Liu L, Ji Y, Smith D, Li N, Chen D (2013) Cytokines in CSF correlate with HIV-associated neurocognitive disorders in the post-HAART era in China. J Neurovirol 19(2):144-149
48. Zelova H, Hosek J (2013) TNF-alpha signalling and inflammation: interactions between old acquaintances. Inflamm res off j Eur Histamine Res Soc [et al] 62(7):641-651. doi: 10.1007/s00011-013-0633-0
49. Zhang H, Legro RS, Zhang J, Zhang L, Chen X, Huang H, Casson PR, Schlaff WD, Diamond MP, Krawetz SA, Coutifaris C, Brzyski RG, Christman GM, Santoro N, Eisenberg E (2010) Decision trees for identifying predictors of treatment effectiveness in clinical trials and its application to ovulation in a study of women with polycystic ovary syndrome. Hum Reprod 25(10):2612-2621. doi: 10.1093/humrep/deq210